Search research articles
Contact Us
Filters
Showing results (1-10 of 140) with videos related to
Page
of 14
Sort By:
Diabetes, Obesity & Metabolism
|
June 4, 2025
The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes
Phil McEwan, Marc Evans
Journal of Comparative Effectiveness Research
|
May 12, 2015
Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice
Marc Evans, Phil McEwan
Applied Health Economics and Health Policy
|
January 19, 2013
Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model
Phil McEwan, Ray Kim, Yong Yuan
Central European Journal of Public Health
|
November 2, 2010
Recent epidemiological results of thyroid cancer in the most radiated territory in Poland
Andrzej Tukiendorf, Leszek Miszczyk, Phil McEwan
Journal of Medical Economics
|
October 18, 2014
Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice--a case-based evaluation
Marc Evans, Phil McEwan, Volker Foos
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 8, 2009
Utility values for obesity and preliminary analysis of the Health Outcomes Data Repository
Simon Dixon, Craig J Currie, Phil McEwan
Advances in Therapy
|
August 14, 2024
The Broader Effects of Delayed Progression to End-Stage Kidney Disease: Delaying the Inevitable or a Meaningful Change?
Ricardo Correa-Rotter, David C Wheeler, Phil McEwan
BMC Nephrology
|
April 25, 2019
Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model
Hayley Bennett, Phil McEwan, Karina Hamilton, et al.
Health and Quality of Life Outcomes
|
November 24, 2012
Characterizing the relationship between health utility and renal function after kidney transplantation in UK and US: a cross-sectional study
Luca Neri, Phil McEwan, Karin Sennfält, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
October 28, 2016
The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
Jason Gordon, Phil McEwan, Michael Hurst, et al.
Page
of 14
Search research articles
Search
Showing results (1-10 of 140) with videos related to
Sort By:
Page
of 14
Diabetes, Obesity & Metabolism
|
June 4, 2025
The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes
Phil McEwan, Marc Evans
Journal of Comparative Effectiveness Research
|
May 12, 2015
Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice
Marc Evans, Phil McEwan
Applied Health Economics and Health Policy
|
January 19, 2013
Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model
Phil McEwan, Ray Kim, Yong Yuan
Central European Journal of Public Health
|
November 2, 2010
Recent epidemiological results of thyroid cancer in the most radiated territory in Poland
Andrzej Tukiendorf, Leszek Miszczyk, Phil McEwan
Journal of Medical Economics
|
October 18, 2014
Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice--a case-based evaluation
Marc Evans, Phil McEwan, Volker Foos
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 8, 2009
Utility values for obesity and preliminary analysis of the Health Outcomes Data Repository
Simon Dixon, Craig J Currie, Phil McEwan
Advances in Therapy
|
August 14, 2024
The Broader Effects of Delayed Progression to End-Stage Kidney Disease: Delaying the Inevitable or a Meaningful Change?
Ricardo Correa-Rotter, David C Wheeler, Phil McEwan
BMC Nephrology
|
April 25, 2019
Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model
Hayley Bennett, Phil McEwan, Karina Hamilton, et al.
Health and Quality of Life Outcomes
|
November 24, 2012
Characterizing the relationship between health utility and renal function after kidney transplantation in UK and US: a cross-sectional study
Luca Neri, Phil McEwan, Karin Sennfält, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
October 28, 2016
The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
Jason Gordon, Phil McEwan, Michael Hurst, et al.
Page
of 14